Empirical therapy advisor

Before culture results are back: how likely is each antibiotic to cover the pathogen of a patient like this one, in this ward, given the last 12 months of results and today's alerts.

Patient

More options · any onset · target 80 % · 2026-08-30
Based on 131 first isolates · ICU · Skin / wound infection · 2025-08-31 → 2026-08-30
Intensive care unit
Per-organism detail: ICU wound resistance view →
No single agent reaches 80 % coverage for this profile. Highest coverage without active warning:
vancomycin 56 % (47 %–64 %)
Best two-drug combination: vancomycin + meropenem covers 98 % (95 %–100 %)
Take cultures before treatment; consider a combination and discuss with infectious diseases if the patient is severely ill.
Not covered: Pseudomonas aeruginosa (13 %), Escherichia coli (13 %), Klebsiella pneumoniae (9 %)
AntibioticCoverage, 12 months (95 % CI)12 mo4 wk
vancomycin VAN
trend · Staphylococcus aureus Gram-positive only
56 %
54 %
n = 13
clindamycin CLI
trend · Staphylococcus aureus Gram-positive only
44 %
38 %
n = 13
meropenem MEM
trend · Pseudomonas aeruginosa reserve
43 %
46 %
n = 13
piperacillin-tazobactam TZP
trend · Pseudomonas aeruginosa broad spectrum
42 %
46 %
n = 13
41 %
46 %
n = 13
29 %
23 %
n = 13
ceftriaxone CRO
trend · Escherichia coli
28 %
15 %
n = 13
20 %
15 %
n = 13
11 %
15 %
n = 13
mecillinam MEC
not for this site
0 %
0 %
n = 13
trimethoprim TMP
not for this site
0 %
0 %
n = 13
nitrofurantoin NIT
not for this site
0 %
0 %
n = 13

Most likely organisms for this profile

Staphylococcus aureus
50 %
Pseudomonas aeruginosa
13 %
Escherichia coli
13 %
Klebsiella pneumoniae
9 %
Proteus mirabilis
8 %
Enterococcus faecalis
5 %

Decision support only: coverage is the share of first isolates from similar patients that were susceptible (an organism not tested for a drug counts as not covered). It does not replace local treatment guidelines, allergy and severity assessment, or clinical judgement. The black tick on each bar is the coverage target; the bracket is the 95 % confidence interval.

AEI · Tyks Laboratoriot × Mylab · JunctionX Turku. Synteettinen aineisto; EARS-Net-luvut: ECDC.